8.13
+0.17(+2.14%)
Currency In USD
| Previous Close | 7.96 |
| Open | 7.99 |
| Day High | 8.18 |
| Day Low | 7.99 |
| 52-Week High | 9.4 |
| 52-Week Low | 3.54 |
| Volume | 28,999 |
| Average Volume | 174,917 |
| Market Cap | 187.39M |
| PE | -23.23 |
| EPS | -0.35 |
| Moving Average 50 Days | 7.93 |
| Moving Average 200 Days | 7.21 |
| Change | 0.17 |
If you invested $1000 in Journey Medical Corporation (DERM) since IPO date, it would be worth $821.21 as of December 25, 2025 at a share price of $8.13. Whereas If you bought $1000 worth of Journey Medical Corporation (DERM) shares 3 years ago, it would be worth $7,008.62 as of December 25, 2025 at a share price of $8.13.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology
GlobeNewswire Inc.
Dec 10, 2025 1:30 PM GMT
Clinical trial achieved all three primary objectives with no significant safety issues being reported Results indicate that Emrosi can be safely used for up to 16 weeks with no detectable impact on skin, GI tract or vaginal microbiota FDA-approved Em
Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025
GlobeNewswire Inc.
Nov 05, 2025 1:30 PM GMT
Company to host conference call to discuss financial results and provide a corporate update on November 12, 2025 at 4:30 p.m. ETSCOTTSDALE, Ariz., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (N
Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference
GlobeNewswire Inc.
Oct 24, 2025 12:30 PM GMT
FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory lesions of rosacea in adults DFD-29 demonstrated s